Nevertheless, differences in the size and frequency of plasma exosomes in patients with genetically more aggressive (IDH WT) gliomas compared to normal donors underscores their potential to reflect tumor burden and, possibly, tumor biology. This evidence concerns the gene IDH2 and neoplasm.